Athira Pharma (ATHA) Competitors $0.37 +0.04 (+12.09%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.38 +0.01 (+3.24%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. ABVC, CUE, GANX, ATRA, RNXT, RENB, ZIVO, QNTM, CRVO, and AADIShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include ABVC BioPharma (ABVC), Cue Biopharma (CUE), Gain Therapeutics (GANX), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), Renovaro (RENB), ZIVO Bioscience (ZIVO), Quantum Biopharma (QNTM), CervoMed (CRVO), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors ABVC BioPharma Cue Biopharma Gain Therapeutics Atara Biotherapeutics RenovoRx Renovaro ZIVO Bioscience Quantum Biopharma CervoMed Aadi Bioscience ABVC BioPharma (NASDAQ:ABVC) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Which has more risk & volatility, ABVC or ATHA? ABVC BioPharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Does the media prefer ABVC or ATHA? In the previous week, Athira Pharma had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.14 beat Athira Pharma's score of -0.65 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Overall Sentiment ABVC BioPharma Positive Athira Pharma Negative Do analysts rate ABVC or ATHA? Athira Pharma has a consensus target price of $11.25, suggesting a potential upside of 2,940.54%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ABVC or ATHA more profitable? Athira Pharma has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-963.46% -29.62% -14.08% Athira Pharma N/A -142.99%-106.40% Do insiders and institutionals hold more shares of ABVC or ATHA? 11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, ABVC or ATHA? ABVC BioPharma has higher revenue and earnings than Athira Pharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$510K157.81-$4.90M-$0.13-36.46Athira PharmaN/AN/A-$96.94M-$2.07-0.18 SummaryAthira Pharma beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.89M$2.87B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.04%P/E Ratio-0.1820.8027.0020.11Price / SalesN/A286.27429.45119.84Price / CashN/A41.1936.8257.86Price / Book0.327.487.985.56Net Income-$96.94M-$55.04M$3.16B$248.40M7 Day Performance22.88%2.44%2.38%4.67%1 Month Performance11.78%1.90%2.17%6.64%1 Year Performance-89.09%4.35%33.80%21.31% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma2.4758 of 5 stars$0.37+12.1%$11.25+2,940.5%-85.9%$12.89MN/A-0.1840ABVCABVC BioPharma0.6794 of 5 stars$3.99+28.3%N/A+521.2%$52.81M$510K-30.6930Positive NewsGap UpHigh Trading VolumeCUECue Biopharma4.073 of 5 stars$0.70+0.7%$3.00+328.4%-25.0%$52.38M$9.29M-1.0560GANXGain Therapeutics2.8397 of 5 stars$1.60-5.3%$8.20+412.5%+50.0%$50.61M$50K-1.8620News CoveragePositive NewsATRAAtara Biotherapeutics4.0952 of 5 stars$8.58+1.3%$17.75+106.9%+16.5%$50.46M$128.94M-2.31330RNXTRenovoRx2.8698 of 5 stars$1.32-2.9%$7.25+449.2%+7.4%$49.74M$240K-3.306RENBRenovaro0.9836 of 5 stars$0.30+2.6%N/A-80.1%$49.72MN/A-0.3920Gap DownZIVOZIVO BioscienceN/A$13.00+8.4%N/A+85.9%$49.62M$15.85K-2.6610Gap UpQNTMQuantum BiopharmaN/A$16.56-2.9%N/AN/A$49.60MN/A-1.04N/ACRVOCervoMed3.3123 of 5 stars$5.87+3.9%$27.63+370.6%-59.2%$49.17M$9.74M-2.694News CoveragePositive NewsAADIAadi Bioscience0.6374 of 5 stars$1.99+5.9%$1.67-16.2%+44.5%$49.15M$25.07M-0.8740 Related Companies and Tools Related Companies ABVC Competitors CUE Competitors GANX Competitors ATRA Competitors RNXT Competitors RENB Competitors ZIVO Competitors QNTM Competitors CRVO Competitors AADI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
